慢性肾脏病(chronic kidney disease，CKD)是危害全人类的公共健康问题之一，贫血是慢性肾脏病的主要并发症，其发生主要是由于肾脏产生红细胞生成素(erythropoietin，EPO)的能力下降所致，除此之外，循环中存在抑制红细胞生成的物质、铁缺乏及铁稳态失衡、慢性炎症状态、红细胞寿命缩短，血液透析过程失血等也参与其发生。肾性贫血不仅会降低患者的生活质量，导致认知功能受损，还会增加心血管疾病住院率、死亡率以及加重社会经济负担。高通量透析是指用高通量透析器代替常规透析器的一种血液净化方式，具有更高的中大分子毒素清除能力，可以更好的纠正贫血。本文研读了近年来发表的一些透析治疗对于贫血纠正的相关研究，旨在阐明高通量血液透析纠正贫血的相关机制。
Chronic kidney disease is one of the public health problems harmful to human beings. Anemia is a major complication in chronic kidney disease patients, mainly caused by the decreased ability of erythropoietin (EPO) production in kidneys. Substances inhibiting erythropoietin production, iron deficiency, imbalance of iron homeostasis, chronic inflammation and short erythrocyte life span are the additional factors for anemia. Blood loss during hemodialysis is also involved in the anemia. Renal anemia may lead to cognitive impairment, increased hospitalization rate due to cardiovascular disease, and higher socio-economic burden, resulting in lower quality of life and higher mortality of the patients. High-flux dialysis is a blood purification method by using high-flux dialyzers instead of conventional dialyzers, having the advantage of efficient removal of medium and large molecular toxins to correct anemia. This paper summarizes the recent studies on the correction of anemia through dialysis, in order to clarify the mechanism of high-flux hemodialysis in the treatment of anemia.
[1]ZHANG L, WANG F, WANG L, et al.Prevalence of chronic kidney disease in China: a cross-sectional survey[J].Lancet, 2012, 379(9818):815-22
[2]FISHBANE S, SPINOWITZ B.Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018[J].Am J Kidney Dis, 2018, 71(3):423-35
[3]肾性贫血诊断与治疗中国专家共识(2018修订版) [J].2018, 34(11): 860-6.
[4]XIANGXUE L, JIALING Z, SHIXIANG W, et al.High Erythropoiesis Resistance Index Is a Significant Predictor of Cardiovascular and All-Cause Mortality in Chinese Maintenance Hemodialysis Patients [J]. 2020, 2020.
[5]BOWRY S K, GATTI E.Impact of hemodialysis therapy on anemia of chronic kidney disease: the potential mechanisms[J].Blood Purif, 2011, 32(3):210-9
[6]SCHNEIDER A, DRECHSLER C, KRANE V, et al.The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: results of the MINOXIS study[J].Clin J Am Soc Nephrol, 2012, 7(1):52-9
[7]LOCATELLI F, ANDRULLI S, PECCHINI F, et al.Effect of high-flux dialysis on the anaemia of haemodialysis patients[J].Nephrol Dial Transplant, 2000, 15(9):1399-409
[8]I M G J, R R, G O, et al.Results from EuCliD (European Clinical Dialysis Database): impact of shifting treatment modality. [J]. 2002, 25(11).
[9]TAKUJI T, SHU K, MAKITO S, et al.Most Important Prognostic Values to Predict Major Adverse Cardiovascular, Cerebrovascular, and Renal Events in Patients with Chronic Kidney Disease Including Hemodialysis for 2 Years. [J]. 2019, 142(1).
[10]SHUXIN L, HONG L, ZHIHONG W, et al.Effect of changing treatment to high-flux hemodialysis (HFHD) on mortality in patients with long-term low flux hemodialysis (LFHD): a propensity score matched cohort study. [J]. 2020, 21(1).
[11]Y.W, K. Z, G. W, et al. PUK1 Low-Flux Hemodialysis Versus High-Flux Hemodialysis for END-STAGE Kidney Disease Meta Analysis [J]. 2020, 22(S).
[12]C P S, S R K, C C J, et al.High-flux versus low-flux membranes for end-stage kidney disease. [J]. 2012, (9).
[13]JOLANTA M, S M J, PIOTR K, et al.Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin. [J]. 2009, 31(10).
[14]AGARWAL A K, YEE J.Hepcidin[J].Adv Chronic Kidney Dis, 2019, 26(4):298-305
[15]YAMAMOTO M, MATSUMOTO T, OHMORI H, et al.Effect of increased blood flow rate on renal anemia and hepcidin concentration in hemodialysis patients[J].BMC Nephrol, 2021, 22(1):221-
[16]LI-HSUAN H M, D A C J, MARIE-AGNèS S, et al.Hepcidin bound to α2-macroglobulin reduces ferroportin-1 expression and enhances its activity at reducing serum iron levels. [J]. 2013, 288(35).
[17]KURAGANO T, FURUTA M, SHIMONAKA Y, et al.The Removal of Serum Hepcidin by Different Dialysis Membranes [J]. 2013, 36(9).
[18]ALICE S-S, SANDRA R, FLáVIO R, et al.Hepcidin in chronic kidney disease anemia. [J]. 2019, 110.
[19]RADTKE H W, FREI U, ERBES P M, et al.Improving anemia by hemodialysis: Effect on serum erythropoietin [J]. 1980, 17(3).
[20]KAREL O, TOMáS R, J?RG V, et al.Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. [J]. 2002, 26(2).
[21]SHUXIN L, LICHAO W, CHUNXIU H, et al.Plasma metabolomics profiling of maintenance hemodialysis based on capillary electrophoresis - time of flight mass spectrometry. [J]. 2017, 7(1).
[22]H H W.Is there a role for adjuvant therapy in patients being treated with epoetin? [J]. 1999, 14 Suppl 2.
[23]DEPNER T A, RIZWAN S, JAMES L A.Effectiveness of low dose erythropoietin: a possible advantage of high flux hemodialysis[J].ASAIO transactions, 1990, 36(3):M223-5
[24]TEATINI U, LIEBCHEN A, NILSSON L G, et al.Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients--A Pilot Investigation[J].Blood Purif, 2016, 41(1-3):80-6
[25]AYLI M, AYLI D, AZAK A, et al.The Effect of High-Flux Hemodialysis on Dialysis-Associated Amyloidosis[J].Renal Failure, 2005, 27(1):31-4
